Abstract
The usual objective during long-term pharmacotherapy is, in large part, to maintain continuity of action of the prescribed drug(s). Continuity of action arises from the continuity of execution of a prescribed dosing regimen that is pharmacologically sound in dose quantity and interval between successive doses. Interruptions in dosing can interrupt drug action, but the consequences vary according to length of interruption, drug, drug formulation, length of the patient's prior exposure to the drug, and the disease being treated.
MeSH terms
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / pharmacokinetics
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / pharmacokinetics
-
Antihypertensive Agents / administration & dosage
-
Antihypertensive Agents / pharmacokinetics
-
Chronic Disease / drug therapy*
-
Dose-Response Relationship, Drug
-
HIV Infections / drug therapy
-
Humans
-
Hypertension / drug therapy
-
Medication Adherence*
-
Prescription Drugs / administration & dosage
-
Prescription Drugs / pharmacokinetics*
-
Prescription Drugs / therapeutic use*
-
Randomized Controlled Trials as Topic
Substances
-
Adrenergic beta-Antagonists
-
Anti-HIV Agents
-
Antihypertensive Agents
-
Prescription Drugs